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1. Abstract  
Plasma membrane Ca2+ ATPases (PMCAs) are intimately involved in the control of 
intracellular Ca2+ concentration. They reduce Ca2+ in the cytosol not only by direct ejection, 
but also by controlling the formation of inositol-1,4,5-trisphosphate and decreasing Ca2+ 
release from the endoplasmic reticulum Ca2+ pool. In mammals four genes (PMCA1-4) are 
expressed, and alternative RNA splicing generates more than twenty variants. The variants 
differ in their regulatory characteristics. They localize into highly specialized membrane 
compartments and respond to the incoming Ca2+ with distinct temporal resolution. The 
expression pattern of variants depends on cell type; a change in this pattern can result in 
perturbed Ca2+ homeostasis and thus altered cell function. Indeed, PMCAs undergo 
remarkable changes in their expression pattern during tumorigenesis that might significantly 
contribute to the unbalanced Ca2+ homeostasis of cancer cells. 
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2. Introduction  
Among the P-type ATPases, plasma membrane Ca2+ ATPases comprise a separate sub-group 
of Ca2+ pumps that is called ATP2B (name of the gene) or PMCA (name of the protein). The 
three types of Ca2+ pumps of the P-type ATPase family - SERCA, SPCA and PMCA - share 
essential basic properties, including membrane topology and reaction mechanism but they 
also display significant differences, particularly in the areas related to regulation. 
Fundamental properties of the PMCA have been discussed in numerous excellent reviews [1-
3].  
PMCAs are encoded by 4 different genes, all are located on different chromosomes; PMCA1 
on 12q21–23, PMCA2 on 3p25.3, PMCA3 on Xq28 and PMCA4 on 1q25–q32 (see refs [1] 
and [4] for review). Alternative splicing of the primary transcripts at two different sites 
produces over 20 different variants. Splicing at site A changes the length of the first 
intracellular loop (A domain) that affects targeting while splicing at site C alters the length of 




A unique property of the PMCA proteins is their complex regulatory feature. The C-terminus 
of PMCAs contains a high affinity calmodulin-binding site that also serves as an auto-
inhibitor. Within the C-terminal region there are also sites for phosphorylation with protein 
kinases, proteolytic sites for caspase-3 and calpain, motifs that control trafficking of the 
pumps and a C-terminal PDZ-binding motif present only in the b splice forms. PMCAs are 
also known to bind to and being activated by acidic phospholipids such as the signaling 
molecule, phosphatidylinositol-4,5-bisphosphate (PI(4,5)P2). 
The basic function of the PMCA is to maintain intracellular Ca2+ homeostasis. When Ca2+ 
increases in the cytosol, it binds to calmodulin (CaM), and then the Ca2+-CaM complex binds 
to several different target proteins to activate down-stream events. Binding of Ca2+-CaM to 
the PMCA releases auto-inhibition of the pump and consequently it becomes active and 
removes Ca2+ from the cytosol. This negative feedback mechanism eventually terminates the 
signal. Thus, the task is relatively simple yet mammalian development resulted in many - over 
20 - distinct PMCA variants. 
PMCAs are expressed in tissue and cell-type specific pattern manner. PMCA1 is the house-
keeping PMCA form present in all cell types. PMCA2 and 3 are typically present in excitable 
cells, in the brain, hair cells of the inner ear or skeletal muscle. The b splice variant of 
PMCA4 is found in relatively large amounts in the heart, endothelial cells, pancreas and in the 
epithelium. The principal piece of the sperm tail expresses specifically the a splice form of 
PMCA4.  
The particular needs of the distinct cell types - being as diverse as neurons in the brain on the 
one hand and cells of the epithelium on the other - are satisfied by the unique 
targeting/trafficking and regulatory characteristics of the individual pump variants. Individual 
targeting features and response-time allow PMCAs to modulate effectively the complex 
spatial-temporal dynamics of Ca2+ signaling events of polarized cells. These unique features 
of PMCAs are complemented with their highly differentiation-specific expression pattern that 
can be significantly altered in less differentiated cancer cells.  
In the present review we will concentrate on recent developments of the PMCA field 
including specific localization and regulatory characteristics of the pumps. We will highlight 
how distinct regulatory features of PMCAs are translated into distinct Ca2+ signaling patterns 
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in the living cells, we will elucidate the dual function of PMCAs in PI(4,5)P2 signaling, and 
finally we will discuss PMCA function in cancer. 
3. Structural elements and regulatory regions of the PMCA  
Structural elements of PMCAs. Sequence homology between P-type ATPases predicted 10 
transmembrane helices, a corresponding set of stalks on the cytoplasmic side and three large 
cytoplasmic domains in the PMCAs (a schematic representation of PMCA structure is shown 
in Figure 1) [3, 5]. The three cytoplasmic domains are 1/ the N domain which binds ATP, 2/ 
the P domain containing an aspartic acid residue that is phosphorylated by ATP during the 
reaction cycle and 3/ the A domain which coordinates the movements of the other domains. 
The transmembrane helices provide the Ca2+-coordinating residues, which can bind one Ca2+ 
ion per reaction cycle [6]. In addition, homology modeling of the PMCA has detected a nearly 
continuous positively charged ring in the membrane-proximal stalk region that is missing 
from the SERCA structure [7]. Thus, PMCAs follow the positive-inside rule of plasma 
membrane proteins like the recently crystalized Zn transporting P-type ATPase [8]. Being a 
transmembrane protein, PMCA interacts with lipids and the presence of lipids is needed for 
activity. Reconstitution of the PMCA into a neutral phospholipid bilayer enhances the enzyme 
turnover rate [9] but more acidic phospholipids are needed for a fully functional pump [10].   
Conformational changes during the enzyme cycle. Similarly to other P-type ATPases, the 
PMCA has been proposed to undergo a series of structural and chemical transitions during its 
reaction cycle. Conventionally, the cycle is initiated by binding of Ca2+ to the high Ca2+ 
affinity E1 state followed by ATP binding and phosphoenzyme (EP) formation. The cycle is 
completed by translocation of Ca2+ through the membrane, dephosphorylation and regaining 
the E1 conformation from the low Ca2+ affinity E2 state that allows the enzyme to begin a 
new cycle. Crystal structures at different conformational states [11]  and kinetic analysis [12] 
of the SERCA pump have suggested that SERCA probably binds ATP first (E2.ATP) 
followed by Ca2+ binding (ATP.E1.2Ca2+) and phosphoenzyme formation (ADP.E1P. 2Ca2+).   
Recently, conformational states of the reaction cycle of PMCA have been determined using 
specific photoactivatable lipid probes [13]. These lipid probes have allowed the measurement 
of conformational changes between the inhibited and Ca2+- calmodulin activated states of the 
pump [14]. From these data, equilibrium constants for various ligand binding, regulation of 
Ca2+ transport in the presence of ATP or vanadate and conformational movements of 
functional domains [15] have been determined. These authors determined the functional cycle 
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of ATP binding and hydrolysis by PMCA and found that in resting condition the pump exists 
in two intermediate states, E1ATP and E2ATP, to which Ca2+ could bind and initiate ATP 
driven Ca2+ transport.  
Regulatory regions. PMCA is a bigger molecule than the other P-type ATPases; two of the 
extra regions contain extra regulatory functions including regulation of activity and changes 
in localization. Localization of the PMCAs is mainly controlled by alternative RNA splicing 
at site A in the first intracellular loop while regulation of activity has been related mostly to 
the C-tail. Importantly, alternative RNA splicing affects both regulatory regions, generating 
multiple versions of the PMCA with distinct regulatory and targeting functions, according to 
the needs of the particular cell type.  
Regulatory regions - the first intracellular loop. Alternative splicing at site A occurs in the 
region encoding the first intracellular loop (Figure 1) where a single exon is either included or 
excluded in the mature transcripts, producing the x and z splice variants of PMCAs. In 
mammalian PMCA2, one or two additional exons can be inserted at the A splice site, 
producing further splice variants y and w [3]. The w PMCA splice variant has the longest 
insert (45 amino acid residues) in its first intracellular loop; this insert targets PMCA2 to the 
apical membrane of polarized cells [16].  
Regulatory regions - the C-tail. Alternative splicing at site C affects the cytosolic C-terminal 
tail and produces splice variants, a, b, c, d, e; among those the most frequently occurring ones 
are the a and b forms (Figure 1). The C-tails of the b splice variants of the PMCA1-3 isoforms 
have relatively high sequence homology but the PMCA4b isoform is quite different. The C-
tail has been known as the main regulatory unit of the PMCA. Regulatory functions of 
proteins are often carried out by intrinsically disordered regions; such regions provide a large 
interaction surface exposing short linear motifs that allow interactions with different protein 
partners [17, 18]. Indeed, the C-tail of PMCAs shows an enrichment of both polar and 
charged residues typical characteristics of such regions. Analysis by different bio-informatics 
tools (IUPred (http://iupred.enzim.hu/) [19], PONDR (http://www.pondr.com/) [20] and 
PREDISORDER (http://sysbio.rnet.missouri.edu/) [21] predicts that the C-tail of PMCA 
contains both ordered and disordered regions. Figure 2 shows the prediction of disordered 
regions in the C-tail of PMCA4b from Phe1045 to the C-terminal Val1205 and the complex 
pattern of different binding and regulatory sequences within the C-tail. In addition to the 
flexible hinges, C-tail contains an about 30-40-residue-long region (from Asp1080 to Leu1114) 
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that are predicted to be structurally well organized (Figure 2B dashed lines). This region 
overlaps the calmodulin-binding sequence (CBS), which is important for both CaM binding 
and autoinhibitory interactions with the core of PMCA (see below). Another program 
ANCHOR (http://anchor.enzim.hu/) [22] identifies binding sites, which are likely to gain 
stabilizing energy by interacting with globular protein partners. ANCHOR found two peaks 
(Figure2B, blue stripes) within the CBS with relatively high probability to serve as binding 
sites. This agrees with the existence of two anchor sites being involved in the interaction 
between the two lobes of Ca2+-calmodulin (see below). Interestingly, ANCHOR indicates 
strong binding sites at both the previously identified downstream di-leucine-like motif [23] 
and the PDZ-binding tail [24]. Between CBS and the di-leucine-like motif another peak 
suggest additional binding sites within a region known to contain PKC phosphorylation and 
calpain cleavage sites [25-27]. Similar sites in the C-tail are also predicted by the 
DISOPRED3 program (http://bioinf.cs.ucl.ac.uk/psipred/) [28]. The CBS and the PDZ 
binding tail (b variants only) share some sequence homology between the PMCA variants, 
while other motifs (di-leucine-like, phosphorylation and calpain cleavage sites) are present 
only in certain variants. This complex arrangement of sites shows the finely-tuned regulatory 
potential of the C-terminal region.  
The Calmodulin-binding sequence. As discussed above the C-tail of the PMCA contains 
sequence motifs involved in regulation. One of these motifs is the ~28-residue long 
calmodulin-binding sequence (CBS). It was possible to study the interaction of this sequence 
with calmodulin by using the synthetic peptides shown in Table 1.  
Free Ca2+-CaM has an extended dumbbell structure in which two globular domains are 
connected by a helix. Activation of the pump requires binding of Ca2+-CaM to the CBS. The 
details of the conformational changes of CaM and peptides representing the CBS were first 
studied by small angle X-ray scattering, which showed changes in the radius of gyration of 
CaM and its complexes indicating that the binding of C20 to CaM did not alter the extended 
structure of CaM, but that use of C24 caused the complex to collapse into a globular structure 
[29]. An NMR structural study of the interaction between CaM and C20 confirmed that CaM 
did not collapse when C20 was used [30]. A more recent NMR study was done using a longer 
peptide (C28); it found that calmodulin was collapsed and wrapped around the C28 peptide 
utilizing two anchors from the peptide that were 18 residues apart, with Trp1093 as the first 
anchor and Phe1110 the second  [31].  
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Autoinhibitory interactions. An important characteristic of the PMCA isoforms is their basal 
activity, which is their activity without the activator Ca2+-calmodulin. The basal activity of the 
pumps depends on the degree of interaction between the C-tail and the catalytic core. If the 
interaction is strong the pump has low basal activity (PMCA4b and PMCA4a) whereas in the 
case of a weak interaction the basal activity is high (PMCA2 and 3 variants). The basal 
activity is determined by sequences of both the C-tail and the core regions to which the C-tail 
binds. The differences between the structures of the C-tails resulted in a higher basal activity 
of PMCA4a as compared to that of PMCA4b [32]. On the other hand, the high basal activity 
of PMCA2b was attributed to the differences in the core regions rather than to the C-tail [33]. 
Importantly, any change made in the C-tail of PMCA4b that increased the basal activity also 
increased the rate of activation by CaM [33-35], demonstrating that autoinhibitory 
interactions also affect CaM binding. 
The autoinhibition of PMCA is removed by Ca2+-calmodulin-binding or by proteolytic 
removal of the whole C-tail. Interestingly, a caspase-3 cleavage site (Asp1080) is located 5 
residues upstream of the CaM-binding sequence between the inhibitory region and the 
catalytic core of PMCA4b. When caspase-3 is activated during the course of apoptosis, it cuts 
immediately after Asp1080 and removes the complete inhibitory region [36-38]. Moreover, 
mutation of Asp1080 activated PMCA4b suggesting that this site functions as an anchor 
between the autoinhibitor and the catalytic core [34]. Another anchor point is Trp1093 which is 
located in the calmodulin-binding sequence and involved in CaM binding (see above) [35]. 
Intramolecular fluorescence resonance energy transfer between the C- and N-terminal 
segments of the PMCA showed that the N-terminal tail is also involved in the autoinhibition 
[39] and Glu99 was determined as a critical anchor point within this region [40]. 
These complex structural features of PMCAs are manifested in functions specific to each 
variant that allow cells regulate delicately their Ca2+ homeostasis and relevant downstream 
effectors.  
4. Ca2+-calmodulin activation kinetics. 
An important feature of the PMCAs is the tight regulation of their activity. Among other less 
characterized modulators, such as acidic phospholipids and phosphorylation with protein 
kinases, the Ca2+-calmodulin complex (Ca2+-CaM) is the primary regulator of the PMCA. The 
regulatory properties of the PMCA isoforms have been determined by studying cells in which 
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one of the isoforms is dominant. The first studies determined the dissociation constants for 
Ca2+-CaM binding to PMCA4b - the major PMCA form present in red cell membrane - under 
steady state conditions using either red cell membrane vesicles or isolated pump.  Later 
overexpressed cell systems were suited better to compare steady-state, as well as kinetic 
characteristics of the isoforms. The first steady-state studies revealed pumps with high and 
low affinity or more precisely pumps with low and high dissociation constants (Kd) for Ca
2+-
CaM, respectively. As an example PMCA4b binds Ca2+-CaM with high affinity while the 
alternatively spliced variant PMCA4a has low affinity [41]. Most of the other variants tested 
in this respect bind Ca2+-CaM with high affinity [27].  
Measuring kinetics of calmodulin binding and PMCA activation sheds light on further details 
of the regulatory properties of the variants. Kinetic constants of Ca2+-CaM 
binding/dissociation and PMCA activation/inactivation rates at different Ca2+ concentrations 
were determined for the most common variants of PMCA2, 3 and 4 (kinetic characteristics of 
the isoforms are summarized in Figure 3A). These experiments showed that PMCA4b binds 
Ca2+-CaM slowly (low kon) and it remains bound to the pump for couple of minutes (low koff ) 
[42, 43]. Surprisingly, however, PMCA4a binds Ca2+-CaM quickly (high kon) but then - 
unlike from PMCA4b - Ca2+-CaM dissociates from this pump also quickly (high koff), which 
is the reason why PMCA4a has low affinity for Ca2+-CaM (Kd=koff/kon) in spite of its fast 
activation rate  [32]. Because of the rapid inactivation, PMCA4a should have no memory of 
earlier Ca2+ spikes.  The PMCA2 and PMCA3 variants are quickly activated and stay active 
for a long time [44, 45]. This property gives them long lasting memories of earlier Ca2+ 
spikes. Based on the activation rates of the pumps, PMCA4b is referred to as the slow pump 
while the other forms are fast pumps. 
Unfortunately, we know very little of the kinetic characteristics of PMCA1. Although 
PMCA1 is ubiquitous, we do not have access to cells in which it is dominant or expressed in 
appreciable amounts to perform kinetic studies.  PMCA4b has been extensively studied 
because it is the dominant Ca2+ transporter of human red cells. The other forms have been 
made dominant by overexpression, but this has been difficult for PMCA1. In an earlier study 
overexpressed PMCA1 was reported to be highly sensitive to proteolytic degradation in Sf9 
cells [46]. In another study, successful overexpression of functional PMCA1a in rat aortic 
endothelial cells led to altered expression of other elements (SERCA, IP3R, CRAC pathway) 




5. Shaping the Ca2+ signal in live cells. 
The shape of the cytoplasmic calcium signal is determined by the rate of calcium influx 
(through plasma membrane or endomembrane calcium channels) and the rate of subsequent 
calcium removal from the cytosol (by calcium pumps and the Na+/Ca2+ exchanger; this latter 
is present only in certain types of cells) [48, 49]. The calcium signal may be oscillatory or a 
single calcium wave, and the latter could be a transient spike or a sustained signal [50, 51]. 
Surprisingly, among the many factors that are known to shape the Ca2+ signal the plasma 
membrane calcium pumps have not been extensively examined. Most of the existing studies 
discuss the role of PMCAs as part of the extrusion systems but little is known about the 
specific function of the individual isoforms.  
One of the main difficulties of these studies has been the lack of PMCA-specific inhibitors.  
La3+ is an effective PMCA inhibitor [52] but it also inhibits (although with lower affinity) 
Ca2+ channels and other Ca2+ transporters [53]. Carboxyeosine is a potent PMCA inhibitor 
[54]; however, it is a fluorescent compound that may interfere with fluorescent Ca2+ sensors 
used to detect the Ca2+ signal in the living cells. More recently a small molecule inhibitor, 
aurintricarboxylic acid (ATA) was identified by high-throughput screening [55]. While ATA 
was reported to inhibit PMCA4 function specifically at a relatively low concentration, at 
higher concentrations it can affect several vital cellular functions, and therefore, this 
compound should be used with caution in live cells. Caloxins are a family of short peptide 
inhibitors that by now also include isoform-specific versions [56-59]; however, their affinity 
is quite low and they have not been thoroughly tested for specificity in live cells, but they may 
become very useful in the future. 
Alterations in plasma membrane abundance and function.  One aspect of the pumps’ impact 
on Ca2+ signaling is when the expression is either reduced or up-regulated. The lack or the 
over-production of the PMCAs, with concomitant modulation of the expression levels of other 
key components of the Ca2+ signaling toolkit, result in increased Ca2+ influx or efflux and/or 
altered Ca2+ sequestration thus, remodeling calcium signaling of the cells. 
PMCA1, the house-keeping isoform, is ubiquitously expressed in all kinds of cells, most often 
together with one or more other PMCA isoforms. Not surprisingly, the decrease of PMCA1 
expression level and/or activity in cases where it is the obligate or dominant isoform leads to 
abnormal [Ca2+]i handling. In pig coronary artery endothelial cells the PMCA1 activity was 
10 
 
reduced by the selective inhibitor, caloxin1b3, resulting in elevated cytosolic calcium 
concentration [58].  In the vascular smooth muscle cells (VSMCs) of VSMC-specific PMCA1 
KO mice the cytosolic Ca2+ level was also raised resulting higher systolic blood pressure in 
the animals [60]. PMCA1 was suggested to play an essential role in gastric epithelial surface 
repair using a PMCA1+/- model [61]. These authors showed that PMCA1 was responsible for 
the increased extracellular Ca2+ concentration near the damaged cells that was required for the 
repair. On the other hand, there are several data emphasizing the importance of PMCA1 in 
transcellular Ca2+ transport. Intestinal Ca2+ uptake is known to be stimulated by 1,25(OH)2D3 
that induces a gene network involved in the regulation of transcellular Ca2+ uptake. Ribiczey 
and others showed that 1,25(OH)2D3 controls the expression of PMCA1 in enterocytes thus, 
it is particularly involved in the transcellular Ca2+ transport of these cells [62, 63]. 
Transcellular Ca2+ transport is also typical of kidney cells. Although, various kidney cells 
express a diversity of PMCA isoforms [64] it seems that it is the PMCA4 isoform that 
contributes to renal transepithelial Ca2+ flux rather than PMCA1 [65]. 
The substantial alteration of the protein expression pattern is a characteristic feature of certain 
tumors and differentiating cells. There are emerging data regarding the modulation of PMCA 
expression and consequent alteration of the Ca2+ signal during differentiation. Indeed, 
increased PMCA4 expression and thus, enhanced Ca2+ clearance was reported during 
differentiation of breast cancer, gastric and colon carcinoma cell lines [66-68]. The 
downregulation of PMCA4 contributes to tumorigenesis by reorganization of the calcium 
signal that influences proliferative pathways in these cells.  
In tissues and cells of neural origin the expression of the fast PMCA isoforms (PMCA2 
and/or PMCA3) is pronounced. Differentiation of a human neuroblastoma cell line IMR-32 
upregulated the expression of PMCA2, PMCA3 and PMCA4 isoforms that increased Ca2+-
efflux from the cells after depolarization [69]. When PMCA2 and PMCA3 levels were 
reduced in PC12 cell lines, even though several compensatory mechanisms (up-regulation of 
PMCA1, PMCA4 and SERCAs), these cells had decreased capacity to remove calcium [70]. 
This led to altered differentiation abilities of the cells with longer neurites, retracted growth 
cones and more varicosities than in control PC12 cells. Moreover, decreased PMCA2 
expression led to increased susceptibility to apoptosis. Similarly, in an aging brain model, 
where suppressed expression of PMCA2 in embryonic rat brain neurons and SH-SY5Y 
neuroblastoma cells showed disruptions of normal Ca2+ signaling, enhanced cell death to toxic 
stimuli was observed [71].  
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PMCA2 is also abundant in lactating mammary gland along with decreased PMCA4 
expression [72] and in some breast cancer cells the PMCA composition was also reported to 
be changed. Increased intracellular calcium levels were observed in PMCA2 deficient 
mammary epithelial cells that led to increased apoptosis, whereas overexpression of PMCA2b 
in T47D breast cancer cells reduced intracellular calcium and consequently reduced apoptosis 
in response to ionomycin treatment [73]. Resistance to apoptosis indicated by PMCA2 
overexpression might contribute to cancer progression and refer to poor prognosis in breast 
cancer.  
A shift in PMCA level in itself does not necessarily correlate with modified Ca2+ extrusion as 
the pump may not localize properly to the plasma membrane. In subconfluent cultures 
PMCA4 was shown to be localized predominantly in intracellular compartments [23, 74]. 
Increasing confluence enhanced plasma membrane localization of either transiently or 
endogenously expressed PMCA4b, and consequently augmented the Ca2+ extrusion capacity 
of the cells [23]. 
There is growing evidence that several kinds of disease (e.g. deafness, cerebellar ataxia, 
familial spastic paraplegia, etc.) are accompanied by mutations in PMCA genes. Almost all of 
these disorders result in disturbances of the Ca2+ handling of the cells reducing the extrusion 
efficiency and increasing the basal cytosolic Ca2+ level (PMCA2: [75]; PMCA3: [76, 77]; 
PMCA4: [78]. 
Interactions with scaffold and signal molecules. There are several lines of evidence that the 
interactions of PMCAs with different scaffold and signal molecules and/or localization of the 
pump might also influence the local and/or global Ca2+ signaling of the cells. In these 
interactions the activity of either the PMCA and/or its partner is altered. These findings have 
shed light on novel functions of PMCA other than simply extruding excess Ca2+ from cells. 
Through these interactions PMCAs become components of various signaling pathways and 
are able to modify downstream signaling directly. One example is the role of PMCAs during 
T cell activation. When T cells are stimulated an elevated global Ca2+ signal is observed that 
enhances the translocation of NFAT to the nucleus [79]. Soboloff et al. found that both 
STIM1 and PMCA4 are upregulated during lectinphytohemagglutinin (PHA)-induced 
activation of T cells and the subsequent interaction of PMCA with STIM1 reduces PMCA-
mediated [Ca2+]i clearance [80]. Further investigations revealed that the ER resident scaffold 
protein POST also interacts with  PMCAs, STIM1 and other components of the Ca2+ signaling 
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complex [81].  In store-depleted Jurkat cells the STIM1-POST complex inhibited PMCA 
activity resulting in a higher cytosolic Ca2+ level. Presumably, POST might act as an adaptor 
of STIM1-mediated PMCA inhibition during T cell activation. T cell activation was also 
shown to result the re-organization of PMCA to the close proximity of mitochondria at the 
immunological synapse [82]. Mitochondria by rapidly taking up the inflowing Ca2+ reduce 
local Ca2+-dependent PMCA activity thus, contributing to the elevated global Ca2+ signal. 
Another example where PMCA activity is influenced by the interplay with other signal 
molecules is the constitutive interaction of G protein-coupled estrogen receptor 1 
(GPER/GPR30) and PMCA4b via their PDZ-binding motifs (through PSD-95) [83]. Via this 
interaction each molecule affects the other's function, i.e. PMCA is inhibited while 
GPER/GPR30 is activated, resulting in a prolonged Ca2+ signal, thus affecting the activity of 
downstream Ca2+ dependent elements. 
Direct comparison of the isoforms. Most the above mentioned studies investigated the effects 
of PMCAs on the overall Ca2+ handling of the cells. In an earlier study the four main PMCA 
isoforms and their splice variants were expressed in Chinese hamster ovary (CHO) cells and 
their Ca2+ extrusion capacity was compared [84] in response to a G-protein coupled receptor 
agonist. In a more recent paper, the effects of PMCA isoforms were compared in a simplified 
model, where the shape of the Ca2+ signal relied mainly on the interplay between plasma 
membrane channels and PMCAs [85]. In this model three kinetically well-characterized 
PMCA isoforms (PMCA4b, 4a and 2b, respectively) were overexpressed in HeLa and HEK-
293 cells and the down-regulation of store operated Ca2+ entry (SOCE) was compared. 
Surprisingly, the different activation and/or inactivation rates of these isoforms produced 
three distinct Ca2+ signal types (oscillation, transient spike or spike with sustained plateau) 
(Figure 3B-C). Mathematical modeling revealed that delayed activation of the slow PMCA4b 
was required for the formation of the oscillation pattern. It is interesting to note, that similar 
time delayed feedback mechanisms often induce oscillation in physiological systems. Indeed, 
the fast pumps PMCA2b and PMCA4a, which are activated quickly with no delay, could not 
generate such oscillation pattern. In this case a single calcium transient is produced but 
because of the distinct memories of these pumps – PMCA4a gets inactivated quickly while 
PMCA2b remains active for a long time – PMCA4a allows an elevated [Ca2+]i after the spike 
while PMCA2b quickly reduces [Ca2+]i to its basal level. 
An earlier study also showed that plasma membrane Ca2+ pumps contribute to sustained 
intracellular Ca2+ oscillations in human bone marrow–derived mesenchymal stem cells [86]. 
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However, in this case Ca2+ oscillations were generated by IP3 induced Ca
2+ release from ER 
stores and yet blocking of PMCA activity (that was shown to be PMCA4) completely 
eliminated oscillation. Similarly, in airway smooth muscle cells inhibition of PMCA1 and 4 
abolished UTP-induced Ca2+oscillations [87]. Interestingly, in a different system in HEK293 
cells, that express preferably the PMCA1 isoform [85], neither Ca2+ entry nor Ca2+ extrusion 
by PMCA was necessary for sustained Ca2+ oscillation [88].   
The main message of the above studies is that PMCAs being regulated by calmodulin, as well 
as by several scaffold and signal molecules in a complex way can effectively shape Ca2+ 
signals. Moreover, PMCAs themselves can transform Ca2+ transients into distinct patterns: 
oscillation, single spike or a spike with a plateau. The fact that PMCA variants can have such 
a great impact on the Ca2+ signal suggests that loss-of-function mutations or an aberrant 
expression and/or localization pattern could indeed contribute to the unbalanced Ca2+ 
signaling reported in a variety of disease states. 
6. Downstream of Ca2+ signaling – the NFAT pathway 
A change in the pattern of Ca2+ signaling might be coupled to changes in a variety of 
downstream signaling pathways [50, 89]. The role of PMCA as a regulator of downstream 
intracellular Ca2+ signaling has long been suggested. In this respect the nuclear factor of 
activated T-cells (NFAT) - a family of transcription factors regulated by calcineurin [90, 91] - 
has been the best-characterized pathway. A direct interaction was described between the 
calcium/calmodulin dependent phosphatase calcineurin and the catalytic core of both PMCA2 
and PMCA4 resulting in a decreased activation of NFAT [92, 93]. These authors suggested 
that the inhibition of the calcineurin/NFAT pathway was a result of the suppressed activity of 
calcineurin due to its low Ca2+ microenvironment provided by the PMCA. In several breast 
cancer cell lines the same authors showed that by disruption of the interaction between 
calcineurin and PMCA2, the NFAT activity could be restored [94]. Another study suggested 
that PMCA4b interacted through its catalytic domain with the tumor suppressor RASSF1 
protein and this interaction decreased the activation of ERK after epidermal growth factor 
stimulation of the cells [95]. These results suggested that PMCAs can inhibit the NFAT/AP-1 
transcriptional activity in these model systems. 
Distinct roles of PMCAs were proposed during the early and late phases of osteoclast 
differentiation [96]. In undifferentiated osteoclasts receptor activator of nuclear factor κB 
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ligand (RANKL) induces Ca2+ oscillations that trigger the activation of NFATc1, which 
regulates the transcription of osteoclastogenic genes. NFATc1 also binds to the promoter 
region of PMCA1 and 4 and increases their expression. The upregulation of PMCAs has a 
major anti-apoptotic effect in mature osteoclasts. In good accordance with these data 
knockdown of PMCA1 and 4 enhanced Ca2+ oscillation and osteoclastogenesis in bone-
marrow derived macrophages and increased apoptosis in mature osteoclasts, while 
overexpression of PMCA1 or 4 strongly decreased RANKL induced Ca2+ oscillations and 
NFATc1 activity reducing osteoclastogenetic potential. These findings revealed the 
importance of PMCA as a core component of an autoregulatory loop between the NFATc1 
and Ca2+ signaling pathways, and PMCA adjusting the course of osteoclastogenesis. 
Endothelial cells provide another model system where the inhibitory effect of PMCA4 on 
NFAT activation has been described. Baggott et al. showed that overexpression of PMCA4b 
in human umbilical vein endothelial cells (HUVEC) decreased NFAT activity after vascular 
endothelial growth factor (VEGF) activation [97]. Furthermore, PMCA4 deficient mouse lung 
endothelial cells (MLEC) produced increased NFAT activation after stimulation. In addition, 
the expression of NFAT target genes COX2 and RCAN1.4, which are involved in 
angiogenesis, were inhibited by PMCA4 overexpression and were increased by PMCA4 
silencing. These authors also found that PMCA4b overexpression decreased the migratory 
ability of HUVECs while PMCA4 deficient MLECs showed increased migration. It is 
important to note that PMCA4 did not affect cell proliferation and ERK phosphorylation in 
these models. The ability of the cells to form endothelial tubes was also investigated both in 
vitro and in vivo, and as a physiological consequence, PMCA4 decreased blood vessel 
formation and VEGF-induced angiogenesis. 
An opposite effect of PMCA4 variants on NFAT activity was found in vascular smooth 
muscles cells (VSMC) [98]. In VSMCs from PMCA4b knock-out mice the expression of 
NFATc3 was decreased by the increase of two proteins, Decorin (G1 arrest marker) and 
regulator of G-protein signaling-16 (Rgs-16; MAPK inhibitor). This effect could be reversed 
by the overexpression of either PMCA4a or PMCA4b. Decorin and Rgs-16 have been shown 
to inhibit the calcineurin/NFAT pathway; hence PMCA4 by regulating signal molecules of 




An inhibitory effect on NFAT signaling by PMCAs was also shown in neuroendocrine cells 
[99]. In PC12 cells, PMCA2 and PMCA3 are present in addition to the ubiquitous PMCA1 
and 4. Downregulation of PMCA2 or PMCA3 in these cells caused a permanent increase in 
the intracellular Ca2+ level in resting cells and an increased Ca2+ influx after stimulation. This 
led to an elevated activation of NFAT 1 (NFATc2) and 3 (NFATc4) and consequently a 
reduction of dopamine secretion of the cells. These authors also showed that inhibition of 
NFAT with 11R-VIVIT changed splicing of the PMCA isoforms [100] suggesting that NFAT 
could control the production of certain PMCA2 and 3 splice variants in PC12 cells. 
All these results highlight the complex relationship of PMCA and NFAT signaling that 
depends strongly on cell- and tissue types and intracellular localization of the pumps. 
7. Targeting PMCAs to the appropriate membrane compartment 
PMCAs are capable of completing their tasks efficiently when they are correctly placed in the 
right plasma membrane compartment. Localization of the PMCA to these compartments is a 
highly regulated process depending on both the properties of the PMCA variants, interaction 
partners and cell type.  
Controlling plasma membrane abundance of PMCA4b – the C-terminal di-leucine-like motif. 
One way to regulate the function of plasma membrane proteins is to control their 
concentration in the plasma membrane; which is often accomplished by tyrosine- or di-
leucine-based sorting signals [101, 102]. Recent experiments showed that a large portion of 
PMCA4b could reach the plasma membrane only in confluent cell cultures [23]. It was 
suggested that a di-leucine-based sorting signal at the C-tail of PMCA4b controls plasma 
membrane abundance of this pump. Mutation of this motif changed dramatically the 
subcellular distribution of the pump and increased its abundance in the plasma membrane 
compartment. Human PMCA4b has two independent di-leucine-based motifs at its C-tail of 
which the upstream motif (1147LL/LI) is conserved in the b splice variants of all PMCAs 
(PMCA1-4) while the downstream motif (1167LLL), which appears to be the main sorting 
signal, is present exclusively in PMCA4b. The upstream di-leucine motif was identified as a 
basolateral sorting motif in PMCA1b and PMCA2b [103] but not in PMCA4b [23]. 
In some cases the di-leucine-based sorting motif is masked by other molecules that prevent 
the protein containing the motif from internalization (E-cadherin, GABAB receptor) [104, 
105]. In case of PMCA4b no such sorting-motif masking partner has been found, however, 
16 
 
interactions with distinct scaffolding proteins can alter localization of the pump in certain 
membrane compartments as discussed below in more details.  
Cellular distribution of the PMCAs in polarized cells – the role of the A splice site. 
Establishment of cell polarity (in neurons, epithelial and migrating cells,) generating distinct 
plasma membrane compartments requires an even more complex regulation of PMCA 
distribution. Splicing at site A can change distribution of PMCAs in polarized cells (see also 
Section 3). The x and z splice variants of PMCA 1 and 4 localize mostly to the basolateral 
membrane compartment of polarized epithelia of lung, intestine and kidney where they can 
facilitate transcellular Ca2+ fluxes [65, 106]. The w insert at the A splice site is the longest and 
acts as a strong apical signal. One example where the w insert concentrates PMCA in the 
apical compartment is the stereocilia at the apical pole of mammalian sensory hair cells of the 
inner ear where PMCA2w/a is required for normal hearing [107-109]. Interestingly, the size 
rather than the particular sequence of the w insert was critical for apical targeting of 
PMCA2w/a [103]. Another example is the lactating mammary gland where the role of 
PMCA2w/b is to provide milk calcium as demonstrated in PMCA2 knock-out mice [110]. 
Apical membrane localization of PMCA2 has also been reported in salivary glands, where 
Ca2+ is secreted into the saliva by PMCA2 as a part of a transcellular Ca2+ transport system, 
including CaT-Like Ca2+ channels, calbindin-2 and SERCAs [111].  
Cellular distribution of the PMCAs – the role of PDZ interactions. The different sequences 
generated by alternative splicing at the C splice site also influence subcellular localization of 
the PMCAs. At the C-termini of all b variants is a PDZ domain-binding sequence by which 
they can interact with various scaffold proteins [112, 113].  The PDZ-binding sequence in the 
PMCA1b, 2b and 3b variants are identical (-ETSL) while the last amino acid residue is 
different in PMCA4b (-ETSV). This minor change in the binding sequence results in different 
binding partners with varying affinities for the different PMCA isoforms. As a result the 
Na+/H+ exchanger regulatory factor 2 (NHERF2) scaffold protein interacts specifically with 
PMCAs having the –ETSL binding sequence but not with that of the PMCA4b variant [114]. 
It was shown that in polarized MDCK cells PMCA2w/b was anchored to the apical 
cytoskeleton via a PDZ-domain mediated interaction with NHERF2 stabilizing and thus 
further increasing the amount of PMCA in the apical plasma membrane compartment [115]. 
PMCA1b trafficking to the membrane was enhanced in response to muscarinic G-protein 
coupled receptor activation and PDZ interaction with NHERF2 played a key role in 
maintaining the pump at the cell surface [116].  
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A distinct localization pattern could be generated by the interaction between the PDZ-binding 
sequence of the PMCA4x/b variant and its binding partner PSD-95 [117]. PSD-95 is a 
member of the membrane-associated guanylate kinase (MAGUK) scaffold family containing 
multiple protein-protein interaction modules that allow clustering of trans-membrane proteins. 
Co-expression of PMCA4x/b and PSD-95 in COS-7 and Neuro-2A cells increased the plasma 
membrane expression of PMCA4x/b and redistributed it into clusters within the plasma 
membrane. The PMCA4b/PSD-95 clusters were fenced by the underlying actin cytoskeleton 
resulting in reduced lateral mobility of the pump. Thus, distinct binding partners can alter 
local abundance of the pump via different type of contacts between PMCAs and the actin 
cytoskeleton, i.e. anchorage with NHERF2 or fence with PSD-95. Dean et al. also found that 
while in resting platelets little PMCA (PMCA1b and PMCA4b) was associated with the actin 
cytoskeleton, PMCA redistributed dramatically to the actin cytoskeleton upon activation with 
thrombin via PDZ mediated processes [118]. Interestingly, G-actin directly interacts with and 
stimulates the activity of the purified erythrocyte Ca2+ pump independent of the PDZ 
interactions [119]. 
PDZ-interactions can recruit PMCAs into distinct microdomains where they can specifically 
alter the activity of their interacting partners. In cardiomyocytes, where PMCA4b binds to 
neuronal nitric oxide synthase (nNOS) through its C-terminal PDZ-binding sequence, PMCA 
has a major structural function, rather than the global Ca2+ removal, by sustaining the integrity 
of the nNOS signaling complex in a plasma membrane microdomain. In PMCA4 knock-out 
animals more than one third of the nNOS showed cytoplasmic localization eventually 
resulting in increased cardiomyocyte contractility [120, 121].  
PMCA localization in neurons. In neurons PMCA isoforms also show functionally distinct 
distribution pattern. In many neuronal cell types (hippocampal neurons, Purkinje cells, 
interneurons) the different PMCAs are concentrated in different microdomains of dendritic 
spines [24, 122, 123] or the presynaptic terminals [124, 125]; and several lines of evidence 
suggest that they play crucial role in the regulation of Ca2+ signaling at the synapse [124, 126, 
127]. Many studies show that PDZ interactions with scaffolding proteins (e.g. PSD-95) recruit 
PMCA into the appropriate supramolecular complexes in neurons [128, 129]. Homer1 also 
interact with PMCA via its PDZ-binding motif [130]. This interaction was suggested to affect 
both PMCA activity and its recruitment to certain membrane microdomains. Homer2 also 
regulates PMCA4 expression and activity in non-excitable cells, however, not via the PDZ 
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binding motif but rather through a putative Homer-binding sequence located in the N-
terminus of PMCA4 [131]. 
Garside et al. studied the localization of PMCA2 within a synapse enriched preparation in 
cerebellum and showed that PMCA2b interacts with PSD95 and the NMDA glutamate 
receptor subunits NR1 and NR2a at post-synaptic sites and with syntaxin-1A at the pre-
synaptic sites [129]. At the presynaptic plasma membrane of the photoreceptor the 
localization of the PMCA is regulated by a unique protein complex including PSD-95 and 
another scaffolding protein membrane palmitoylated protein 4 (MPP4) [132].  
In the aspiny dendrites of interneurons nicotinic acetylcholine receptors are functionally 
linked to PMCA2b via PSD-95 and the activity of the PMCA2b regulates the number of 
receptor clusters [133]. In different central nervous system (CNS) areas (spinal cord, 
brainstem, and retina) there is a compartmentalized interaction between the neuronal glycine 
transporter 2 (GlyT2), the Na+/Ca2+-exchanger1 (NCX1) and the PMCA2 and PMCA3 
isoforms, that regulates GlyT2 activity. The GlyT2•PMCA2,3•NCX1 complex is found in 
lipid raft domains and PMCA and NCX activities are necessary for GlyT2 activity [134]. 
Studies on PMCA2 knock-out mice revealed that besides regulation of the presynaptic Ca2+ 
handling PMCA can also influence the morphology of neurons. The lack of PMCA2 
dramatically altered the morphology of the Purkinje neurons in cerebellum [135]. Similarly, 
reduced size of the Purkinje cell dendritic tree was observed when PMCA activity was 
inhibited chronically [136]. 
Association of PMCA and lipid rafts. Localization of PMCA also depends on the composition 
of the microdomains (lipid rafts) in the plasma membrane. Sepulveda et al. found that in pig 
cerebellum only the PMCA4 isoform associates with cholesterol/sphingomyelin-rich lipid 
rafts while other PMCA variants are found in the detergent-soluble fractions [137]. In MDCK 
cells PMCA2w/b variant partitioned into low-density membranes associated with lipid rafts in 
the apical membrane. Depletion of membrane cholesterol resulted in reduced lipid raft 
association and loss of PMCA2w/b from the apical membrane [138]. Recently, Jiang et al. 
described that all PMCA isoforms can be located in lipid rafts in rat brain synaptosomal 
membranes. They found that the raft PMCA pool showed the highest specific activity and that 
activity decreased progressively with age [139]. Another study found that both PMCA and 
calmodulin are localized within lipid rafts in primary cultured neurons and this relationship 
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influences the function of the pump. The depletion of cholesterol strongly inhibited the raft-
associated PMCA activity [140]. 
PMCA localization in migrating cells.  
Ca2+ gradients have been recognized between the front and back of different types of 
migrating cells. Recent experiments demonstrated that a front-to-rear polarity of PMCA 
expression resulted in low cytosolic Ca2+ in the front of migrating human endothelial cells and  
suggested that this specific distribution of PMCA was at least partially responsible for the 
typical front-to-rear Ca2+ concentration gradient essential for directed and collective migration 
of endothelial cells [141]. Knocking-down or inhibition of PMCA activity abolished the Ca2+ 
gradient and impaired directed cell migration underlying the importance of PMCA in 
endothelial cell migration.  
All these examples indicate that PMCA has highly specialized roles at distinct membrane 
regions such as cell junctions, post or pre-synaptic densities or lamellipodia. To recruit the 
PMCA to these sites, it is necessary to establish the appropriate protein-protein interaction 
with scaffolding proteins, actin cytoskeleton or regulator partner. These processes are 
determined by the localization signals of PMCAs which are highly various due to the A and 
C-splice sites. Both the C-tail and other regions of the pump variants may have additional, not 
yet recognized, trafficking/localization motifs that may further define their highly specialized 
tasks and shed light on the role of the less acknowledged forms of this large Ca2+ATPase 
family.  
8. A novel role of PMCAs in PI(4,5)P2 signaling 
 
PI(4,5)P2 is a key signaling phospholipid molecule of the inner leaflet of the plasma 
membrane involved in cell motility, adhesion, exocytosis, endocytosis, and in many other 
vital cellular processes [142]. It regulates various channels and pumps, forms clusters with a 
variety of PI(4,5)P2 -binding proteins and controls their function. PI(4,5)P2 binding may occur 
via electrostatic interactions with polybasic regions and/or through binding to specific binding 
pockets of proteins.  
PI(4,5)P2 has long been known to activate PMCA [143]. Two acidic phospholipid-binding 
sites have been identified: one is the so called AL region near the A splice site close to 
transmembrane segment M3 [144, 145] and the other is the positively charged calmodulin 
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binding sequence at the C-tail (Figure 1). More recently, in addition to the previously 
determined positively charged regions, homology models of PMCA4b showed the presence of 
a ring of basic residues (the blue collar) on the cytoplasmic side, in the stalk region  next to 
the membrane [146]. Placement of PI(4,5)P2 molecules at random positions near the stalk 
disclosed 4 probable binding pockets in the collar of the PMCA4b molecule. Since almost all 
basic residues of the pockets are conserved among PMCAs similar PI(4,5)P2 binding pockets 
are expected to be formed in nearly all PMCA isoforms. 
In regions of the membrane which have a high concentration of PMCA, there will be an 
equilibrium between free and bound PI(4,5)P2. The relation between free and bound PI(4,5)P2 
and its probable impact on cellular Ca2+ signaling is shown schematically in Figure 4. 
PI(4,5)P2 molecules which bind to PMCA are protected from hydrolysis to inositol-
triphosphate (IP3) and diacylglycerol [146]. Since IP3 triggers release of Ca
2+ from 
intracellular stores [147], binding to PMCA will limit release of Ca2+. Recently Pena et al 
showed that by binding PI(4,5)P2 the myristoylated alanine-rich C-kinase substrate 
(MARCKS) also could control intracellular calcium mobilization during acrosomal exocytosis 
[148]. However, in addition to sequestering PI(4,5)P2, PMCAs can remove Ca
2+ from the 
vicinity of PI(4,5)P2 molecules protecting them from Ca
2+-dependent phospholipase C 
mediated hydrolysis resulting in less IP3 release throughout the agonist stimulation phase. 
The above findings suggest that PMCAs are not simply Ca2+ gatekeepers but they offer 
double-protection for the cells during Ca2+ signaling by means of removing excess Ca2+ from 
the cytosol and controlling intracellular Ca2+ store depletion in the same time. 
9. PMCAs in cancer cells and tumors. 
The expression of PMCAs 2-4 is cell/tissue-type and differentiation-stage specific while the 
housekeeping form PMCA1 is expressed in the early embryonic state and does not change 
drastically during development. However, a specific splice shift from PMCA1b to PMCA1a 
occurs during the development of neurons [123, 149]. Tumorigenesis is generally associated 
with inhibition of cell differentiation. Numerous observations indicate that remodeling of 
intracellular Ca2+ homeostasis is an important step of tumorigenesis and metastasis formation 
[150-156]. Several types of Ca2+ entry channels – STIM/ORAI, secretory pathway calcium 
ATPase 2 (SPCA2)/ORAI1 and TRP channels - have been reported to be upregulated in 
cancer cells that may lead to an overall rise in intracellular Ca2+ concentration and 
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consequently to increased tumor progression. In addition, Ca2+ channels were shown to 
promote migration and invasion [157, 158]. In line with these observations, an altered 
expression of the PMCAs has been also reported in a variety of cancer cell types that was 
accompanied by a significantly altered Ca2+ signaling pattern. PMCA1 and PMCA2 mRNA 
expression levels were found to be upregulated, while PMCA4 expression was downregulated 
in breast cancer cell lines compared to non-tumorigenic breast epithelial cells [159, 160]. In 
addition, pronounced PMCA4b expression in normal, mature ductal breast epithelium has also 
been demonstrated [68]. Furthermore, downregulation of PMCA4 expression in colon 
carcinoma has been reported while a comparatively high level of PMCA4 mRNA level was 
detected in normal colon tissue [74]. Interestingly, specific downregulation of the PMCA4 
protein expression level was observed in high-grade colon adenoma, colon cancer and lymph 
node metastasis [161]. These studies suggest that the abundance of PMCA4 is highly sensitive 
to the degree of differentiation of cells and that the expression of PMCA4 (PMCA4b in 
particular) is downregulated in tumors. In contrast to the frequent downregulation of 
PMCA4b expression in tumors, changes in the expression of PMCA1 do not show a clear 
enough picture to accurately predict its role in tumorigenesis. While a modest upregulation of 
PMCA1 has been described in breast cancer cell lines, downregulation of its expression was 
seen in SV40 transformed skin and lung fibroblast [162] as well as in oral cancers where 
PMCA1 was found to be epigenetically inactivated [163]. 
Upregulation of PMCA4b in differentiating cancer cell models. Epigenetic downregulation of 
the expression of differentiation-associated genes by deregulation of DNA methylation and 
histone acetylation are typical characteristics of cancer cells. Histone deacetylase (HDAC) 
inhibitors such as short chain fatty acids, suberoylanilide hydroxamic acid (Vorinostat) or 
valproic acid are known to induce differentiation and apoptosis, and block proliferation of 
tumor cells; hence they have been used in clinical trials as anticancer drugs [164-166]. While 
decreased PMCA expression was found in poorly differentiated tumor cells, differentiation 
inducing HDAC inhibitors were shown to upregulate the expression of distinct PMCA 
isoforms in the same type of cells. In MCF-7 breast carcinoma cells induction of cell 
differentiation by HDAC inhibitors or phorbol ester led to the selective enhancement of 
PMCA4b expression [68]. Moreover, it has been shown that induction of cell differentiation 
of colon and gastric carcinoma cell lines also leads to the upregulation of PMCA4b protein 
levels [67, 167]. It is important to note, that no changes in the expression of either PMCA1 or 
PMCA2 were described in either of the above differentiation models of colon or breast cancer 
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cell lines. In these model systems differentiation-induced increase in PMCA4b expression 
resulted in enhanced Ca2+ clearance from cells suggesting that PMCA4b could, in principle, 
inhibit Ca2+ entry-mediated tumor progression.  
Correlation of Ca2+ pump expression profiles in cancer cells. PMCA4b upregulation is often 
accompanied by the differentiation-specific induction of the SERCA3 protein in cells of 
epithelial origin such as colon, lung and breast cancer cells [68, 152, 168, 169]. Also, 
downregulation of SERCA3 expression in tumors has been demonstrated [170, 171]. 
Interestingly, SERCA3 is controlled by Ca2+ itself; it gets activated only at relatively high 
Ca2+ concentrations that might be attained mostly locally near the opening of Ca2+ channels 
[172]. In that sense, SERCA3 may also allow larger Ca2+ signals to develop similarly to the 
PMCA4b pump with its delayed response to the same signal. Thus, simultaneous upregulation 
of SERCA3 and PMCA4b may be particularly well suited to the specific Ca2+ signaling 
character of the differentiated epithelial cells. 
Little is known about the potential involvement of the third family of Ca2+-ATPases, the 
secretory pathway calcium ATPases (SPCA), in cancer. SPCA1 was reported to have cell type 
specific effects: SPCA1 haploinsufficiency increased the incidence of squamous cell tumors 
of the skin and esophagus [173], whereas SPCA1 levels were significantly elevated in clinical 
samples of breast cancer of the basal subtype [174]. Alterations in SPCA1 levels had no 
substantial effect on global cytosolic calcium signaling. Rather, it affected the processing of 
proteins important in tumor progression. On the other hand, besides its conventional Ca2+ 
transporting role, a novel function was attributed to SPCA2, that is triggering store 
independent Ca2+ entry by direct interaction with plasma membrane Ca2+ channels [151]. 
Accordingly, high levels of SPCA2 in cancer cells result in sustained elevation of cytoplasmic 
Ca2+ concentration. Considering that cancerous cells often have reduced PMCA expression 
(thus reduced Ca2+ extrusion capacity), the effect of increased SPCA2 levels is synergistic 
with the decreased PMCA levels in tumorigenesis.  
Conclusions 
Since the early discovery of the erythrocyte Ca2+ pump [175] research progressed first on 
understanding the basic properties of PMCAs using biochemical and later molecular 
biological tools, isolated pumps or membrane preparations. The discovery of an increasing 
number of pump variants with distinct characteristics has raised further interests on their 
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biological function. From the major phenotypes of PMCA knockout mice we learned that 
PMCA1 is the house-keeping form; PMCA2 is essential for hearing and for providing proper 
amount of milk Ca2+; and PMCA4 for male fertility. From the many studies both in situ and in 
vivo we also learned that the functional diversity of the pump isoforms probably arises from a 
not yet clearly understood regulation of their gene expression and the structural divergence 
between the regulatory regions of the variants. Accordingly, 1/ PMCA expression is 
development-, cell- and tissue-type specific; 2/ Subcellular localization, abundance and 
activity of individual PMCA isoforms can be altered by alternative splicing and interactions 
with specific adaptor, regulator and/or scaffold proteins; and 3/ Expression of pumps with 
distinct regulatory properties can have significant impact on the Ca2+ signal and can generate 
typical patterns such as oscillation, single spike or a spike with a plateau. These distinct types 
of signals then could lead to diverse downstream events altering cellular function and 
eventually cell fate. 
Conventionally, the function of PMCAs is to maintain cellular Ca2+ homeostasis by removing 
excess Ca2+ from the cytosol. In addition to this vitally important task, a recently recognized 
new role of the PMCA is to control the abundance of free PI(4,5)P2 molecules in the plasma 
membrane and the formation of IP3, and thereby agonist induced discharge of the Ca
2+ pool. 
The great diversity and cellular specificity of PMCAs imply that disturbances in any of the 
above PMCA function (altered expression, activity and/or cellular localization) may result in 
disease causing properties. Mutations in the ATP2B2 and ATP2B3 genes can cause deafness, 
or cerebellar ataxia, respectively. Reduced expression of PMCA1 has been associated with 
altered bone mineralization and gastric epithelial wound healing among others. Reduced 
expression of PMCA4, on the other hand, often coincides with tumorigenesis or may be 
linked to male infertility.  
In summary, although we have learned a great deal about the structural basis of PMCAs’ 
function, we still do not have a 3-D crystal structure of the molecule to understand structural 
details of auto-inhibition, interactions with regulator proteins and lipids nor their reaction 
steps. Although, we understand quite well why so many PMCA isoforms are needed to satisfy 
cellular needs, we still do not have isoform specific and high affinity small molecule 
inhibitors to ease studying the role of individual PMCA variants in cell function. During the 
last years it also became apparent that altered levels of PMCA abundance might be related to 
tumor progression, but the exact mechanisms that could control PMCA expression are not 
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very well understood. Thus, future research aiming to answer these questions may help to find 
new ways to prevent PMCA-associated diseases and reduce the risk of cancer. 
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Figure legends 
Figure 1: Model of plasma membrane Ca2+ATPase 
 
Schematic representation of membrane topology of the PMCA is shown on top. Catalytic 
phosphorylation site (P), ATP-binding site (ATP) , Acidic lipid (AL) binding region  and 
calmodulin-binding sequence (CBS) are indicated. Among the alternative splice variants, only 
the A splice variants of PMCA2 isoform and C splice variants of PMCA4 isoform are shown. 
 
Figure 2: C-terminal tail of PMCA4b 
 
A, Schematic representation illustrating the composition of the binding sites and other motifs 
in the C-terminal tail of PMCA4b. Abbreviations of previously determined binding sites: CBS 
– calmodulin-binding sequence, LLL – di-leucine-like motif starting at 1167Leu [23], PDZB – 
PDZ-binding sequence [24], PKC – protein kinase C phosphorylation sites [27], pp60src – 
pp60src phosphorylation site (1176Tyr) [176]. The red lines show protease cleavage sites.  
B, Disordered probability of the C-tail. The continuous and dotted lines show the disorder 
probability of the C-tail calculated by IUPRED (red), PREDISORDER (blue) and PONDR-
VSL2 (green) predictors. Regions predicted to be disordered (scores are higher than 0.5) are 
marked with continuous lines. The blue stripes in the background indicate disordered binding 
regions predicted by ANCHOR program.  
 
Figure 3: Ca2+ signal patterns formed by different PMCA variants  
 
A, Different kinetic properties of the PMCA variants. The points refer to the activation and 
inactivation character (slow or fast) of the individual PMCA variants according to the 
parameters described in [42-45]. 
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B-C, PMCA specific SOCE mediated Ca2+ signal patterns in epithelial cells. Simulations were 
performed using the kinetic parameters of the model from Paszty et al. [85], with permission 
from AAAS. B, Low expression level of PMCA; C1- C3, High expression levels of PMCA4b, 
PMCA2b and PMCA4a variants, respectively. 
 
Figure 4: Binding of PI(4,5)P2 to PMCA decreases the intracellular Ca2+ level by two 
mechanisms. 
 
This scheme shows dynamic equilibrium between free and PMCA-bound PI(4,5)P2. At a 
relatively high PMCA abundance PI(4,5)P2 will bind to the PMCA, depleting the pool of free 
PI(4,5)P2. In this case, less free PI(4,5)P2 will be available for hydrolysis to IP3. Less IP3 will 
then release less Ca2+ from the intracellular stores, diminishing the Ca2+ signal in response to 
extracellular stimuli. At the same time, by binding PI(4,5)P2 PMCA becomes more active 
hence removing Ca2+ from the cell more rapidly than in its unbound state. 
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